GM-CSF+ B cells can contribute to proinflammatory macrophage responses in vivo in MS patients, and anti-CD20 diminishes macrophage proinflammatory responses in these treated patients due to the removal of GM-CSF+ B cells (95). Here, CSF2 is linked to myeloid sarcoma.